Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

• Status: Completed
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE).

("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Fondaparinux; PENTA

Criteria

Inclusion Criteria:

• Patients with acute pulmonary thromboembolism or acute deep venous thrombosis

• Fondaparinux injection must be prescribed for the first time

Exclusion Criteria:

• Not applicable